Last updated September 9, 2026
Key finding
The addition of anagliptin significantly reduced HbA1c by 0.6% from baseline at Week 24.
This study evaluated the efficacy and safety of anagliptin in patients with type 2 diabetes who were inadequately controlled on insulin and metformin, finding a significant reduction in HbA1c levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of anagliptin in patients with type 2 diabetes who were inadequately controlled on insulin and metformin, finding a significant reduction in HbA1c levels.
These findings are significant for clinicians managing patients with type 2 diabetes who are not achieving adequate glycemic control with insulin and metformin alone. The ability of anagliptin to lower HbA1c levels could help improve overall diabetes management and reduce the risk of complications associated with uncontrolled diabetes.
The study was limited to a specific population of patients already on insulin and metformin. The sample size and duration may limit the generalizability of the findings. Other potential confounding factors were not measured.
Published in
Publication details and source links for this paper.
Ji EJ, Sung HC, Min KM, et al. Efficacy and safety of anagliptin in patients with type 2 diabetes inadequately controlled on insulin and metformin. Diabetes, Obesity & Metabolism. 2025;27(9):5351-5355. doi:10.1111/dom.16557
Anagliptin reduced HbA1c by 0.6% (p=0.009) at Week 24.
No change in HbA1c in the placebo group.
No significant differences in body weight, BMI, or lipid levels between groups.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Anagliptin 100 mg twice daily and BMI, Blood glucose, Body weight, and 6 more.
This study contributes evidence to
Primary intervention
Anagliptin 100 mg twice daily
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
9
Evidence pairs
1676
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Anagliptin 100 mg twice daily → Blood glucose
Anagliptin 100 mg twice daily → Blood glucose
Anagliptin 100 mg twice daily → Fasting Plasma Glucose (FPG)
Anagliptin 100 mg twice daily → Fasting Plasma Glucose (FPG)
Anagliptin 100 mg twice daily → HDL-cholesterol change
Anagliptin 100 mg twice daily → HDL-cholesterol change
Anagliptin 100 mg twice daily → LDL cholesterol
Anagliptin 100 mg twice daily → LDL cholesterol
Anagliptin 100 mg twice daily → Total cholesterol
Anagliptin 100 mg twice daily → Total cholesterol
Anagliptin 100 mg twice daily → Triglyceride change
Anagliptin 100 mg twice daily → Triglyceride change
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Anagliptin 100 mg twice daily and Fasting Glucose, Anagliptin 100 mg twice daily and Body Mass Index.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on Anagliptin 100 mg twice daily
Contributes to Anagliptin 100 mg twice daily evidence base.
All studies measuring Body Mass Index
Measures Body Mass Index as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Anagliptin 100 mg twice daily appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear effect of Anagliptin 100 mg twice daily on BMI.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Anagliptin 100 mg twice daily for blood glucose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear effect of Anagliptin 100 mg twice daily on body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
